15 results
8-K
EX-99.1
APTO
Aptose Biosciences Inc
14 May 24
Aptose Reports Results for the First Quarter 2024
4:15pm
clinical trials, and reduced manufacturing costs. In the comparative period in 2023, tuspetinib program costs included the healthy volunteer study, which
8-K
EX-99.1
APTO
Aptose Biosciences Inc
26 Mar 24
Aptose Reports Results for the Fourth Quarter and Full Year 2023
4:04pm
clinical trial, our healthy volunteer trial, manufacturing activities to support clinical development, purchase of clinical trial materials, and related
424B4
APTO
Aptose Biosciences Inc
26 Jan 24
Prospectus supplement with pricing info
5:30pm
volunteer trial, manufacturing activities to support clinical development, and related expenses.
Program costs for luxeptinib decreased by approximately … period represent the enrollment of patients in our APTIVATE clinical trial, our healthy volunteer trial, manufacturing activities to support clinical
8-K
EX-99.1
715rycdrc4935x1 9e
9 Nov 23
Aptose Reports Results for the Third Quarter 2023
4:15pm
8-K
EX-99.1
732zk
10 Aug 23
Aptose Reports Results for the Second Quarter 2023
4:10pm
8-K
EX-99.1
e8ge1
8 May 23
Aptose Reports Results for the First Quarter 2023
4:05pm
6-K
EX-99.1
d7rlmij66monl qbpoo
6 Nov 18
Current report (foreign)
4:40pm
- Prev
- 1
- Next